Curative effect of mosapride and Shugan Jieyu capsule in the treatment of functional dyspepsia and Influence on brain-gut peptide

Abstract

Objective To investigate the curative effect and mechanism of mosapride and Shugan Jieyu capsule in the treatment of functional dyspepsia(FD). Methods One hundred and ten cases patients with FD were divided into two groups according to the digital random table method, with 55 cases in each group.The control group took mosapride tablets orally(5 mg/times, 3 times/d, 30 min before meals), the treatment group took with Shugan Jieyu capsule orally(2 pellets/times, 2 times/d, orally with warm water on morning and evening) on the basis of treatment of the control group.Two groups were treated continuously for 4 weeks.The symptoms score and total effective before and after treatment were compared, and plasma Leptin(Leptin), Ghrelin and gastric dynamic element(MTL) levels of the two groups before and after treatment were compared.The two groups were followed up for 6 months after treatment, the recurrence rate of the two groups was compared. Results The symptoms integral of the treatment group after treatment was lower than that of the control group((4.97±1.85) points vs.(7.35±2.28) points, t=6.011, P<0.01), the total effective rate was higher than that of the control group(94.5%(52/55) vs.81.8%(45/55), χ2=4.274, P=0.039), the improvement of plasma Leptin ((13.10±2.07) μg/L vs.(14.66±2.11) μg/L, t=3.914, P=0.001), Ghrelin ((3.52±0.70) ng/L vs.(2.95±0.67)ng/L, t=4.363, P<0.01), MTL((281.47±61.09) ng/L vs.(242.31±65.28) ng/L, t=3.248, P=0.002) levels were better than those of the control group, the recurrence rate of 6 months was lower than that of the control group(7.5%(5/53) vs.24.4%(11/45), χ2=4.124, P=0.041), the difference was statistically significant. Conclusion Mosapride tablets combined with Shugan Jieyu capsule can benefit the liver symptom, and also can reduce the recurrence rate, it has curative effect on FD, its mechanism may be related to the improvement of BGP levels disorder in patients with FD. Key words: Mosapride; Shugan Jieyu capsule; Functional dyspepsia; Brain-gut peptides